Vident Advisory’s Recursion Pharmaceuticals RXRX Stock Holding History

Vident Advisory's RXRX Position: Q2 2026 in Review

Vident Advisory increased its Recursion Pharmaceuticals (RXRX) stake by 26% in Q2 2026, buying an estimated $12K and bringing the position to 17,660 shares worth $64.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1902.

Vident Advisory first reported a position in RXRX in Q3 2023 and has held it in 8 quarters since. The position peaked at $208K in Q3 2023. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

• Vident Advisory held 17,660 shares of Recursion Pharmaceuticals worth $64.8K as of Q2 2026.
• Vident Advisory bought 3,611 Recursion Pharmaceuticals shares in Q2 2026, an estimated $12K.
• Recursion Pharmaceuticals made up ﹤0.01% of Vident Advisory's portfolio in Q2 2026, its #1902 holding.
• Vident Advisory first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 8 quarters since.
• Vident Advisory's Recursion Pharmaceuticals position peaked at $208K in Q3 2023.
• 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.